---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-284535"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:49:11.119762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences Q3 net loss narrows to $0.18/sh; cash $44M; appoints Scott Brun to board

## Summary
- Q3 2022 net loss $3.4M ($0.18/share) vs $7.8M ($0.54) in Q3 2021; R&D expenses fell to $1.4M.
- Cash and equivalents $44.0M at Sept 30, 2022; 21.0M shares outstanding; no revenue.
- Lead candidate FB-102 on track for clinic late 2023/early 2024; addressable market >$6B.
- Appointed Scott Brun, M.D. to Board (effective Nov 10); ex-Head of AbbVie Ventures and Product Development.

## SEC filing metadata
- accession: 0001193125-22-284535
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522284535/0001193125-22-284535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522284535/d419341d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-284535
- JSON: https://secwatch.observer/filing/0001193125-22-284535.json
- Plain text: https://secwatch.observer/filing/0001193125-22-284535.txt

## Key facts
- Earnings Releases
  Forte Biosciences, Inc. reported the quarter ended September 30, 2022 results: EPS ($0.18).
  - Period: the quarter ended September 30, 2022
  - EPS: ($0.18)
  - Result: reported results
  source text: Net losses per share were ($0.18) and ($0.54) for the three months ended September 30, 2022 and 2021, and ($0.56) and ($1.34) for the nine months ended September 30, 2022 and 2021, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312522284535/0001193125-22-284535-index.htm
- Executive change
  Scott Brun was appointed as Director at Forte Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 10, 2022, the Board of Directors (the “Board) of the Company, upon recommendation of the Nominating and Governance Committee of the Board, appointed Scott Brun, M.D. to the Board, effective November 10, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312522284535/0001193125-22-284535-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.